Rituximab and biosimilars - equivalence and reciprocity.
Cancer is a debilitating disease affecting millions of people daily. Over the years, cancer treatment has advanced in leaps and bounds. Antibodies are important breakthrough therapeutic agents for cancer. These agents, proteins produced by B lymphocytes of the immune system in response to antigens, bind to receptors on cell surfaces so that the antigen-antibody complexes can be recognized and destroyed by phagocytes. While each B cell synthesizes only one kind of antibody, an entire population of different types of B cells and their respective antibodies are produced in response to various antigens to which the organism had been exposed. However, to be useful clinically, substantial amounts of a single antibody must be generated from a single ancestral B cell. These antibodies produced by a specific population of B cells are the monoclonal antibodies that have become the cornerstone of treatment for cancer and many immunologic illnesses. The purpose of this report is to provide an overview of the clinical development of biosimilars in clinical oncology, focusing on rituximab and like biosimilars.
South Carolina College of Pharmacy, Columbia, SC, USA ; Arnold School of Public Health of the University of South Carolina, Columbia, SC, USA.
Zaina P
ZP
Qureshi
South Carolina College of Pharmacy, Columbia, SC, USA.
Jametta S
JS
Magwood
Department of Biological Sciences, George Washington University, Washington, DC, USA.
Sarveshwari
S
Singh
South Carolina College of Pharmacy, Columbia, SC, USA ; Arnold School of Public Health of the University of South Carolina, Columbia, SC, USA ; Hollings Cancer Center, Charleston, SC, USA.
Charles L
CL
Bennett
biosimilars; cancer treatment; rituximab